Immuron's IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81%
Top-line data showed treatment with IMM-124E (bovine colostrum) produced a statistically significant reduction in serum lipopolysaccharide (LPS) levels compared to placebo. LPS is associated with the progression of NASH.
https://seekingalpha.com/news/3337676-immurons-immminus-124e-shows-encouraging-action-mid-stage-nash-study-shares-ahead-81-percent
Filter by Year:
- Immuron’s shares surge on demonstrating proof of concept for liver drug candidate
- Immuron and US Department of Defense look to develop silver bullet for gastro infections
- Immuron's IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81%
- Blockbuster Results from IMC’s NASH Liver Therapy Trials
- Immuron reports positive clinical study results in the fight against fatty liver disease
- Results in: IMC’s lead drug reduces major factor in liver inflammation
- US Defense finishes latest research on Immuron’s Travelan®
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
